Is transesophageal echocardiogram mandatory in patients undergoing ablation of atrial fibrillation with uninterrupted novel oral anticoagulants? Results from a prospective multicenter registry

Luigi Di Biase, David F. Briceno, Chintan Trivedi, Sanghamitra Mohanty, Carola Gianni, J. David Burkhardt, Prasant Mohanty, Rong Bai, Sampath Gunda, Rodney Horton, Shane Bailey, Javier E. Sanchez, Amin Al-Ahmad, Patrick Hranitzky, G. Joseph Gallinghouse, Yaruva Madhu Reddy, Jason Zagrodzky, Richard Hongo, Salwa Beheiry, Dhanunjaya LakkireddyAndrea Natale

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: Transesophageal echocardiography (TEE) is recommended in patients undergoing atrial fibrillation (AF) ablation, but use of this strategy is variable. Objective: To evaluate whether TEE is necessary before AF ablation in patients treated with novel oral anticoagulants (NOACs). Methods: We performed a prospective multicenter registry of AF patients undergoing radiofrequency catheter ablation on uninterrupted NOACs (apixaban and rivaroxaban). All patients were on NOACs for at least 4 weeks before ablation. Heparin bolus was administered to all patients before transseptal catheterization to maintain a target activated clotting time above 300 seconds. A subset of 86 patients underwent brain diffuse magnetic resonance imaging (dMRI) to detect silent cerebral ischemia (SCI). Results: A total of 970 patients (514 [53%] apixaban patients and 456 [47%] rivaroxaban patients) were enrolled for this study. The mean age was 69.5 ± 9.0 years, with 824 patients (85%) having nonparoxysmal AF, and 636 patients (65.6%) were male. The average CHA2DS2-VASc score was 3.01 ± 1.3 and CHADS2 score was ≥2 in 609 patients (62.8%). Intracardiac echocardiogram ruled out left atrial appendage thrombus in all patients whose left atrial appendage was visualized (692, 71%), and detected "smoke" in 407 patients (42%). SCI at postprocedure dMRI was detected in 2.3% (2/86). One thromboembolic event (transient ischemic attack) (0.10%) with positive dMRI occurred in a patient on uninterrupted rivaroxaban with longstanding persistent AF. Conclusion: Our study illustrates that performing AF ablation while on uninterrupted apixaban and rivaroxaban without TEE is feasible and safe. This finding has important clinical and economic relevance.

Original languageEnglish (US)
JournalHeart Rhythm
DOIs
StateAccepted/In press - 2016

Fingerprint

Anticoagulants
Atrial Fibrillation
Registries
Transesophageal Echocardiography
Atrial Appendage
Magnetic Resonance Imaging
Brain Ischemia
Catheter Ablation
Transient Ischemic Attack
Smoke
Catheterization
Heparin
Thrombosis
Economics

Keywords

  • Ablation
  • Atrial fibrillation
  • NOAC
  • Transesophageal echocardiogram
  • Uninterrupted anticoagulation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Is transesophageal echocardiogram mandatory in patients undergoing ablation of atrial fibrillation with uninterrupted novel oral anticoagulants? Results from a prospective multicenter registry. / Di Biase, Luigi; Briceno, David F.; Trivedi, Chintan; Mohanty, Sanghamitra; Gianni, Carola; Burkhardt, J. David; Mohanty, Prasant; Bai, Rong; Gunda, Sampath; Horton, Rodney; Bailey, Shane; Sanchez, Javier E.; Al-Ahmad, Amin; Hranitzky, Patrick; Gallinghouse, G. Joseph; Reddy, Yaruva Madhu; Zagrodzky, Jason; Hongo, Richard; Beheiry, Salwa; Lakkireddy, Dhanunjaya; Natale, Andrea.

In: Heart Rhythm, 2016.

Research output: Contribution to journalArticle

Di Biase, L, Briceno, DF, Trivedi, C, Mohanty, S, Gianni, C, Burkhardt, JD, Mohanty, P, Bai, R, Gunda, S, Horton, R, Bailey, S, Sanchez, JE, Al-Ahmad, A, Hranitzky, P, Gallinghouse, GJ, Reddy, YM, Zagrodzky, J, Hongo, R, Beheiry, S, Lakkireddy, D & Natale, A 2016, 'Is transesophageal echocardiogram mandatory in patients undergoing ablation of atrial fibrillation with uninterrupted novel oral anticoagulants? Results from a prospective multicenter registry', Heart Rhythm. https://doi.org/10.1016/j.hrthm.2016.03.024
Di Biase, Luigi ; Briceno, David F. ; Trivedi, Chintan ; Mohanty, Sanghamitra ; Gianni, Carola ; Burkhardt, J. David ; Mohanty, Prasant ; Bai, Rong ; Gunda, Sampath ; Horton, Rodney ; Bailey, Shane ; Sanchez, Javier E. ; Al-Ahmad, Amin ; Hranitzky, Patrick ; Gallinghouse, G. Joseph ; Reddy, Yaruva Madhu ; Zagrodzky, Jason ; Hongo, Richard ; Beheiry, Salwa ; Lakkireddy, Dhanunjaya ; Natale, Andrea. / Is transesophageal echocardiogram mandatory in patients undergoing ablation of atrial fibrillation with uninterrupted novel oral anticoagulants? Results from a prospective multicenter registry. In: Heart Rhythm. 2016.
@article{273cd3098e254764a61ee4610cbb25ba,
title = "Is transesophageal echocardiogram mandatory in patients undergoing ablation of atrial fibrillation with uninterrupted novel oral anticoagulants? Results from a prospective multicenter registry",
abstract = "Background: Transesophageal echocardiography (TEE) is recommended in patients undergoing atrial fibrillation (AF) ablation, but use of this strategy is variable. Objective: To evaluate whether TEE is necessary before AF ablation in patients treated with novel oral anticoagulants (NOACs). Methods: We performed a prospective multicenter registry of AF patients undergoing radiofrequency catheter ablation on uninterrupted NOACs (apixaban and rivaroxaban). All patients were on NOACs for at least 4 weeks before ablation. Heparin bolus was administered to all patients before transseptal catheterization to maintain a target activated clotting time above 300 seconds. A subset of 86 patients underwent brain diffuse magnetic resonance imaging (dMRI) to detect silent cerebral ischemia (SCI). Results: A total of 970 patients (514 [53{\%}] apixaban patients and 456 [47{\%}] rivaroxaban patients) were enrolled for this study. The mean age was 69.5 ± 9.0 years, with 824 patients (85{\%}) having nonparoxysmal AF, and 636 patients (65.6{\%}) were male. The average CHA2DS2-VASc score was 3.01 ± 1.3 and CHADS2 score was ≥2 in 609 patients (62.8{\%}). Intracardiac echocardiogram ruled out left atrial appendage thrombus in all patients whose left atrial appendage was visualized (692, 71{\%}), and detected {"}smoke{"} in 407 patients (42{\%}). SCI at postprocedure dMRI was detected in 2.3{\%} (2/86). One thromboembolic event (transient ischemic attack) (0.10{\%}) with positive dMRI occurred in a patient on uninterrupted rivaroxaban with longstanding persistent AF. Conclusion: Our study illustrates that performing AF ablation while on uninterrupted apixaban and rivaroxaban without TEE is feasible and safe. This finding has important clinical and economic relevance.",
keywords = "Ablation, Atrial fibrillation, NOAC, Transesophageal echocardiogram, Uninterrupted anticoagulation",
author = "{Di Biase}, Luigi and Briceno, {David F.} and Chintan Trivedi and Sanghamitra Mohanty and Carola Gianni and Burkhardt, {J. David} and Prasant Mohanty and Rong Bai and Sampath Gunda and Rodney Horton and Shane Bailey and Sanchez, {Javier E.} and Amin Al-Ahmad and Patrick Hranitzky and Gallinghouse, {G. Joseph} and Reddy, {Yaruva Madhu} and Jason Zagrodzky and Richard Hongo and Salwa Beheiry and Dhanunjaya Lakkireddy and Andrea Natale",
year = "2016",
doi = "10.1016/j.hrthm.2016.03.024",
language = "English (US)",
journal = "Heart Rhythm",
issn = "1547-5271",
publisher = "Elsevier",

}

TY - JOUR

T1 - Is transesophageal echocardiogram mandatory in patients undergoing ablation of atrial fibrillation with uninterrupted novel oral anticoagulants? Results from a prospective multicenter registry

AU - Di Biase, Luigi

AU - Briceno, David F.

AU - Trivedi, Chintan

AU - Mohanty, Sanghamitra

AU - Gianni, Carola

AU - Burkhardt, J. David

AU - Mohanty, Prasant

AU - Bai, Rong

AU - Gunda, Sampath

AU - Horton, Rodney

AU - Bailey, Shane

AU - Sanchez, Javier E.

AU - Al-Ahmad, Amin

AU - Hranitzky, Patrick

AU - Gallinghouse, G. Joseph

AU - Reddy, Yaruva Madhu

AU - Zagrodzky, Jason

AU - Hongo, Richard

AU - Beheiry, Salwa

AU - Lakkireddy, Dhanunjaya

AU - Natale, Andrea

PY - 2016

Y1 - 2016

N2 - Background: Transesophageal echocardiography (TEE) is recommended in patients undergoing atrial fibrillation (AF) ablation, but use of this strategy is variable. Objective: To evaluate whether TEE is necessary before AF ablation in patients treated with novel oral anticoagulants (NOACs). Methods: We performed a prospective multicenter registry of AF patients undergoing radiofrequency catheter ablation on uninterrupted NOACs (apixaban and rivaroxaban). All patients were on NOACs for at least 4 weeks before ablation. Heparin bolus was administered to all patients before transseptal catheterization to maintain a target activated clotting time above 300 seconds. A subset of 86 patients underwent brain diffuse magnetic resonance imaging (dMRI) to detect silent cerebral ischemia (SCI). Results: A total of 970 patients (514 [53%] apixaban patients and 456 [47%] rivaroxaban patients) were enrolled for this study. The mean age was 69.5 ± 9.0 years, with 824 patients (85%) having nonparoxysmal AF, and 636 patients (65.6%) were male. The average CHA2DS2-VASc score was 3.01 ± 1.3 and CHADS2 score was ≥2 in 609 patients (62.8%). Intracardiac echocardiogram ruled out left atrial appendage thrombus in all patients whose left atrial appendage was visualized (692, 71%), and detected "smoke" in 407 patients (42%). SCI at postprocedure dMRI was detected in 2.3% (2/86). One thromboembolic event (transient ischemic attack) (0.10%) with positive dMRI occurred in a patient on uninterrupted rivaroxaban with longstanding persistent AF. Conclusion: Our study illustrates that performing AF ablation while on uninterrupted apixaban and rivaroxaban without TEE is feasible and safe. This finding has important clinical and economic relevance.

AB - Background: Transesophageal echocardiography (TEE) is recommended in patients undergoing atrial fibrillation (AF) ablation, but use of this strategy is variable. Objective: To evaluate whether TEE is necessary before AF ablation in patients treated with novel oral anticoagulants (NOACs). Methods: We performed a prospective multicenter registry of AF patients undergoing radiofrequency catheter ablation on uninterrupted NOACs (apixaban and rivaroxaban). All patients were on NOACs for at least 4 weeks before ablation. Heparin bolus was administered to all patients before transseptal catheterization to maintain a target activated clotting time above 300 seconds. A subset of 86 patients underwent brain diffuse magnetic resonance imaging (dMRI) to detect silent cerebral ischemia (SCI). Results: A total of 970 patients (514 [53%] apixaban patients and 456 [47%] rivaroxaban patients) were enrolled for this study. The mean age was 69.5 ± 9.0 years, with 824 patients (85%) having nonparoxysmal AF, and 636 patients (65.6%) were male. The average CHA2DS2-VASc score was 3.01 ± 1.3 and CHADS2 score was ≥2 in 609 patients (62.8%). Intracardiac echocardiogram ruled out left atrial appendage thrombus in all patients whose left atrial appendage was visualized (692, 71%), and detected "smoke" in 407 patients (42%). SCI at postprocedure dMRI was detected in 2.3% (2/86). One thromboembolic event (transient ischemic attack) (0.10%) with positive dMRI occurred in a patient on uninterrupted rivaroxaban with longstanding persistent AF. Conclusion: Our study illustrates that performing AF ablation while on uninterrupted apixaban and rivaroxaban without TEE is feasible and safe. This finding has important clinical and economic relevance.

KW - Ablation

KW - Atrial fibrillation

KW - NOAC

KW - Transesophageal echocardiogram

KW - Uninterrupted anticoagulation

UR - http://www.scopus.com/inward/record.url?scp=84964691756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964691756&partnerID=8YFLogxK

U2 - 10.1016/j.hrthm.2016.03.024

DO - 10.1016/j.hrthm.2016.03.024

M3 - Article

C2 - 26994940

AN - SCOPUS:84964691756

JO - Heart Rhythm

JF - Heart Rhythm

SN - 1547-5271

ER -